

Date: October 2, 2026

To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI - 400 051 Symbol: AUROPHARMA	To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, MUMBAI - 400 001 Scrip Code: 524804
---	---

Dear Sir/Madam,

Re: Disclosure under Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.

Ref: Our letters dated July 23, 2026, September 12, 2026 and October 1, 2026.

We refer to our letters dated **July 23, 2026, September 12, 2026 and October 01, 2026**, informing that Apitoria Pharma Private Limited ("Apitoria"), a wholly owned subsidiary of the Company, is acquiring the Contract Research Services business of A1 Biochem Group.

This is to inform you that, A1 Biochem USA Inc ("A1 USA Inc"), which is a wholly owned subsidiary of A1 Biochem Labs (India) Private Limited ("A1 Labs India"), has acquired 100% ownership of A1 Biochem Labs LLC ("A1 Labs LLC") in accordance with the terms of the Definitive Agreements entered into for the acquisition of A1 Biochem Group. A1 Labs LLC is operating from USA and will now be a step-down subsidiary of A1 Labs India.

The disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Part A of Schedule III of the aforesaid regulations, is attached as **Annexure A**.

This is for your information and record.

Thanking you,

Yours faithfully,

For AUROBINDO PHARMA LIMITED

Digitally signed by ADI REDDY

BADDIGAM

Date: 2026.10.02 17:54:59 +05'30'

B. Adi Reddy

Company Secretary

Encl: as above

AUROBINDO PHARMA LIMITED

(CIN : L24239TG1986PLC015190)

www.aurobindo.com

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.
Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad-500038 Telangana., India Tel: +91 40 2373 6370/2374 7340 Fax: +91 40 2374 1080/2374 6833
Email: info@aurobindo.com Website: www.aurobindo.com

Annexure – A

Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

a) Name of the target entity, details in brief such as size, turnover etc.;	i) Name of the Target: A1 Biochem Labs LLC (“A1 Labs LLC”) <u>Registered Office:</u> 5598 Marvin K. Moss Lane, Suite 2022, Wilmington, North Carolina, Zip Code: 28409. ii) Details of the Target: A1 Labs LLC is engaged in providing contract research and chemistry services to pharmaceutical companies, biotechnology companies, including custom synthesis and medicinal chemistry from its scientific laboratory located in Wilmington, North Carolina, USA. A1 Labs LLC was led by Dr. Rajendra Gadikota, who has 25+ years of experience in this business and shall continue to be employed with A1 Labs LLC after the acquisition. A1 Labs LLC was incorporated in September 2015. It has total sales of USD 9.23 Million during the calendar year ending 31st December 2024 and USD 5.92 Million during the calendar year ending 31st December 2025.
b) Whether the acquisition would fall within related party transaction(s) and whether the promoter / promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”;	The acquisition of A1 Labs LLC by A1 USA Inc, a wholly owned subsidiary of A1 Labs India, will fall within the definition of a related party transaction. A1 Labs LLC is being acquired from Dr. Rajendra Gadikota, who is also a Director of A1 Labs India. The promoter / promoter group/ group companies of the Company have no interest in the transaction. The acquisition is being undertaken at arm’s length.
c) Industry to which the entity being acquired belongs;	Pharmaceuticals industry

AUROBINDO PHARMA LIMITED

(CIN : L24239TG1986PLC015190)

www.aurobindo.com

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.
Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad -500038 Telangana., India Tel: +91 40 2373 6370/2374 7340 Fax: +91 40 2374 1080/2374 6833
Email: info@aurobindo.com Website: www.aurobindo.com

d) Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	The transaction aligns with the Company's strategic objective of expanding its presence in the life cycle of Active Pharmaceutical Ingredients (API) business. Apitoria and A1 Labs India are currently engaged in large-scale, regulatory-compliant API manufacturing. Through this acquisition of front-end research and development capability, the Company will be able to create a dedicated Contract Research, Development and Manufacturing (CRDMO) platform. It will expand the portfolio of the Company facilitating full service, longer life cycle engagement with the customers. This transaction is complementary to the current API manufacturing business of Apitoria and A1 Labs India.
e) Brief details of any governmental or regulatory approvals required for the acquisition.	Transaction is not subject to any governmental or regulatory approvals.
f) Indicative time period for completion of the acquisition;	The acquisition has been completed on 2 nd October 2026 subject to customary conditions prescribed under the Definitive Agreements.
g) Consideration - whether cash consideration or share swap or any other form and details of the same;	Cash consideration of USD 15.247 Mn.
h) Cost of acquisition or the price at which the shares/ business are acquired;	A1 Labs LLC does not have share capital represented by shares. A1 USA Inc has acquired 100% membership interest in A1 Labs LLC for the aforementioned consideration.
i) Percentage of shareholding / control acquired and / or number of shares acquired;	A1 USA Inc has acquired 100% ownership of A1 Labs LLC.

AUROBINDO PHARMA LIMITED

(CIN : L24239TG1986PLC015190)

www.aurobindo.com

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.
Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad -500038 Telangana., India Tel: +91 40 2373 6370/2374 7340 Fax: +91 40 2374 1080/2374 6833
Email: info@aurobindo.com Website: www.aurobindo.com

j) Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	A1 Labs LLC is engaged in providing contract research and chemistry services to pharmaceutical companies, biotechnology companies, including custom synthesis and medicinal chemistry. A1 Labs LLC operates through a leased scientific laboratory located in Wilmington, North Carolina. A1 Labs LLC was incorporated in September 2015 with the registered office in Wilmington, North Carolina, USA. A1 Labs LLC's turnover during the last three calendar years is as follows: 31st December 2023: USD 6.35 Million 31st December 2024: USD 9.23 Million 31st December 2025: USD 5.92 Million
---	---

Digitally signed by ADI REDDY BADDIGAM
Date: 2026.10.02 17:55:38 +05'30'

AUROBINDO PHARMA LIMITED

(CIN : L24239TG1986PLC015190)

www.aurobindo.com

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.
Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad -500038 Telangana., India Tel: +91 40 2373 6370/2374 7340 Fax: +91 40 2374 1080/2374 6833
Email: info@aurobindo.com Website: www.aurobindo.com